New Digital Tool Detects Memory Decline Years Before Symptoms Appear
Cambridge-backed PREMAZ measures memory precision to catch Alzheimer's warning signs far earlier than standard cognitive tests.
Summary
A London health tech startup called Prema Cognition has raised $730,000 to expand PREMAZ, a digital cognitive assessment built with the University of Cambridge Memory Lab. Unlike standard memory tests that only flag problems after noticeable decline, PREMAZ measures subtle shifts in how precisely the brain stores and retrieves information — potentially catching early Alzheimer's warning signs years sooner. The tool is already deployed across 30-plus clinics in the UK and US. Early detection matters increasingly because newer Alzheimer's therapies appear most effective at the earliest disease stages, before irreversible brain damage occurs. The round was oversubscribed, drawing investors from biotech, pharma, and longevity healthcare, signaling growing conviction that cognitive health is central to the future of aging medicine.
Detailed Summary
One of the most urgent problems in dementia care is the gap between when disease begins and when it gets detected. By the time standard cognitive tests raise a flag, years of neurological damage may already be done. Prema Cognition, a Cambridge-derived health tech company, is targeting that gap with PREMAZ — a clinician-ready digital assessment designed to catch memory decline far earlier than existing tools.
PREMAZ focuses on what the company calls memory precision: not just whether someone remembers something, but how accurately they remember it. Small distortions in memory retrieval, invisible in routine conversation or standard clinical assessments, may signal early neurodegeneration. The technology draws on over a decade of research from the University of Cambridge Memory Lab and is currently deployed in more than 30 clinics across the UK and United States.
The timing is clinically significant. A new generation of Alzheimer's therapeutics — including recently approved anti-amyloid drugs — appears most effective during the earliest stages of disease, before large-scale brain damage occurs. Healthcare systems, however, still struggle to identify eligible patients early enough. Earlier detection tools like PREMAZ could directly expand the window in which these treatments can meaningfully intervene.
The startup has closed a $730,000 funding round led by SFC Capital, drawing interest from biotech, pharma, enterprise software, and longevity-focused healthcare investors. The round was oversubscribed, reflecting broader investor appetite for clinically grounded brain health tools rather than consumer wellness products with weak evidence bases.
Caveats remain. The $730,000 raise is modest, and PREMAZ has not yet published peer-reviewed clinical validation data in this article's reporting. Independent evidence confirming sensitivity, specificity, and real-world predictive accuracy would be needed before clinicians or patients should draw firm conclusions. Still, the approach is scientifically plausible and the clinical need is well established.
Key Findings
- PREMAZ detects subtle memory precision changes potentially years before standard cognitive tests identify decline.
- Tool is already in use across 30+ UK and US clinics, suggesting early real-world clinical adoption.
- Earlier Alzheimer's detection is critical because new therapies work best before irreversible brain damage occurs.
- Round was oversubscribed, signaling strong investor confidence in clinically grounded cognitive health tools.
- Memory precision — accuracy of recall, not just presence — may be a more sensitive early biomarker than recall alone.
Methodology
This is a news report summarizing a funding announcement and product overview, not a peer-reviewed study. The source, Longevity.Technology, is a credible industry publication covering aging and health tech. Evidence basis is largely company-reported; independent clinical validation data for PREMAZ is not cited in the article.
Study Limitations
No peer-reviewed validation data for PREMAZ is cited; performance metrics such as sensitivity and specificity are not reported. The funding amount is small, raising questions about scale and long-term development capacity. Claims about detecting decline years earlier require independent clinical trial confirmation before widespread clinical reliance is warranted.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.